IMMIX BIOPHARMA INC. - COMMON STOCK

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

23 4 2025 09:04:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

10 2 2025 08:35:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

07 1 2025 08:34:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

19 12 2024 08:35:00 提供 Nasdaq GlobeNewswire

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

16 12 2024 08:48:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

10 12 2024 08:39:00 提供 Nasdaq GlobeNewswire

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

09 12 2024 08:33:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

25 11 2024 08:32:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

02 10 2024 08:32:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

19 9 2024 08:31:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

28 8 2024 08:32:00 提供 Nasdaq GlobeNewswire

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

25 7 2024 20:31:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

08 7 2024 08:31:00 提供 Nasdaq GlobeNewswire

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

17 6 2024 08:35:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

10 5 2024 08:35:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

29 4 2024 08:39:00 提供 Nasdaq GlobeNewswire

Immix Biopharma on Track to Dose NXC-201 Patients in United States

18 4 2024 08:32:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

15 4 2024 08:36:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

20 3 2024 08:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

05 3 2024 08:35:00 提供 Nasdaq GlobeNewswire